Work

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

Year: 2013

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-013-2286-7

Authors: L. Rhoda Molife, Sarah M. Rudman, Salma Alam, Daniel S.-W. Tan, Hartmut Kristeleit, Gary Middleton, David Propper, Liz Bent, Peter Stopfer, Martina Uttenreuther-Fischer, Gudrun Wallenstein, Johann de Bono, James Spicer

Institutions: Institute of Cancer Research, Royal Marsden Hospital, National Health Service, Guy's and St Thomas' NHS Foundation Trust, Royal Surrey County Hospital, Barts Cancer Institute, Boehringer Ingelheim (United Kingdom), Boehringer Ingelheim (Germany), King's College London

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Royal Marsden NHS Foundation Trust, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Cancer Research UK, National Institutes of Health

OpenAlex ID: W1977449846

FWCI: 1.784

Cites: 29

Cited by: 18

Related to: 10